KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ginkgo Bioworks Holdings (DNA) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Ginkgo Bioworks Holdings (DNA) over the last 5 years, with Sep 2025 value amounting to -207.05%.

  • Ginkgo Bioworks Holdings' EBITDA Margin fell 14594.00% to -207.05% in Q3 2025 from the same period last year, while for Sep 2025 it was -187.04%, marking a year-over-year increase of 11028.00%. This contributed to the annual value of -242.39% for FY2024, which is 11106.00% up from last year.
  • As of Q3 2025, Ginkgo Bioworks Holdings' EBITDA Margin stood at -207.05%, which was down 77.70% from -116.52% recorded in Q2 2025.
  • Over the past 5 years, Ginkgo Bioworks Holdings' EBITDA Margin peaked at -34.37% during Q3 2021, and registered a low of -1,134.55% during Q4 2021.
  • Its 3-year average for EBITDA Margin is -296.92%, with a median of -249.97% in 2024.
  • Examining YoY changes over the last 5 years, Ginkgo Bioworks Holdings' EBITDA Margin showed a top increase of 96,382bps in 2022 and a maximum decrease of 97,853bps in 2022.
  • Quarterly analysis of 5 years shows Ginkgo Bioworks Holdings' EBITDA Margin stood at -1,134.55% in 2021, then skyrocketed by 96,382bps to -170.73% in 2022, then slumped by 42,576bps to -596.49% in 2023, then surged by 34,653bps to -249.97% in 2024, then tumbled by 14,594bps to -207.05% in 2025.
  • Its last three reported values are -207.05% in Q3 2025, -116.52% for Q2 2025, and -186.27% during Q1 2025.